Regulatory Science and Policy Subcommittee
The AACR established the Regulatory Science and Policy Subcommittee in March of 2011 to support the FDA’s endeavor to modernize the regulatory process and accommodate the fast pace of innovation in science and technology. The subcommittee leads the AACR’s efforts to facilitate scientific exchange among stakeholders from academia, industry, advocacy, and government to unleash the true potential of regulatory science to serve patients. In order for the latest research to inform regulators, regulatory guidelines and regulatory policy, regulators must keep abreast with developments in cancer research. Scientists also benefit from an understanding of the regulatory process, which can facilitate their own research programs and speed the translation of discoveries into new and improved interventions.
The subcommittee is dedicated to bringing together and providing an open forum for stakeholder engagement. It is also actively engaged in the development and implementation of programmatic and policy initiatives to improve the development, evaluation and regulation of cancer drugs, biologics and diagnostics.
Subcommittee Members
Kenneth C. Anderson, MD, FAACR
Subcommittee Chairperson
Program Director and Chief, Division of Hematologic Neoplasia, Kraft Family Professor of Medicine
Harvard Medical School, Dana-Farber Cancer Institute
Boston, Massachusetts
James L. Abbruzzese, MD, FACP
Chief, Division of Medical Oncology, Department of Medicine, Associate Director for Clinical Research
Duke Cancer Institute
Durham, North Carolina
Chris Boshoff, MD, PhD
Chief Development Officer
Pfizer Oncology
New York, New York
William S. Dalton, PhD, MD
Founder and Chief Executive Officer
M2Gen
Tampa, Florida
Raymond N. DuBois, MD, PhD
Dean, College of Medicine
Medical University of South Carolina
Charleston, South Carolina
Susan M. Galbraith, MBBCh, PhD
Executive Vice-President, Oncology R&D
AstraZeneca
Cambridge, England
Judy E. Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Dana-Farber Cancer Institute
Boston, Massachusetts
Levi A. Garraway, MD, PhD
Global Head of Product Development, Chief Medical Officer
F. Hoffman-LaRoche Ltd.
South San Francisco, California
Richard B. Gaynor, MD
President, Research and Development
Neon Therapeutics
Cambridge, Massachusetts
William N. Hait, MD, PhD
Global Head of External Innovation
Johnson & Johnson Pharmaceutical R&D
Raritan, New Jersey
Eric B. Haura, MD
Senior Member
Moffitt Cancer Center
Tampa, Florida
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Associate Director for Translational Research
Yale Cancer Center
New Haven, Connecticut
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Scientific Director, Belfer Institute for Applied Cancer Science
Dana-Farber Cancer Institute
Boston, Massachusetts
Chitkala Kalidas, PhD
Vice President, Head Oncology Regulatory Affairs
Bayer
New York, New York
Peter F. Lebowitz, MD, PhD
Senior Vice President, Global Therapeutic Area Head, Oncology
Janssen Research and Development, LLC
Wayne, Pennsylvania
John E. Leonard, PhD
Senior Vice President, Development
Vaccinex Inc.
Rochester, New York
Thomas J. Lynch, Jr., MD
President and Director, Fred Hutchinson Cancer Research Center
Seattle, Washington
Elaine R. Mardis, PhD
Co-executive Director, Institute for Genomic Medicine
Nationwide Children’s Hospital
Columbus, Ohio
David M. Reese, MD
Vice President, Medical Sciences
Amgen Inc.
Los Angeles, California
Eric H. Rubin, MD
Vice President and Therapeutic Area Head, Oncology Early Dev.
Merck Research Laboratories
Charles L. Sawyers, MD
Chair, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, New York
Howard I. Scher, MD
Co-chair, Center for Mechanism Based Therapy
Memorial Sloan Kettering Cancer Center
Mehdi Shahidi, MD
Corporate Vice President, Global Head of Medicine, Oncology
Boehringer Ingelheim
Sutton, England
Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research
Washington, D.C.
Suzanne L. Topalian, MD
Professor, Surgery and Oncology, Johns Hopkins University School of Medicine
Director, Melanoma Program, Sidney Kimmel Cancer Center
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Laura J. van ‘t Veer, PhD
Professor, Department of Laboratory Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Victor E. Velculescu, MD, PhD
Co-director of Cancer Biology and Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Verena Voelter, MD
Head of U.S. Clinical Development and Medical Affairs
Novartis Oncology
East Hanover, New Jersey
AACR Staff Contact
Nicholas Waren, PhD
Assistant Director, Regulatory Science and Policy
Email